BitGo Reports Soaring Revenue, Widening Losses, and Declining Platform Assets Amid Unresolved Internal Control Issues

summarizeSummary

BitGo Holdings reported a significant revenue increase but also a sharp rise in net losses and negative Adjusted EBITDA, alongside a notable decline in Assets on Platform and Assets Staked. The company continues to grapple with un-remediated material weaknesses in internal controls and an ongoing $100 million lawsuit.

check_boxKey Events

• Net Loss and Adjusted EBITDA Worsen

  Net loss increased by 136.3% to $60.7 million in Q1 2026 from $25.7 million in Q1 2025. Adjusted EBITDA shifted from a $3.9 million profit to a $1.7 million loss year-over-year.

• Revenue Surges on Digital Asset Sales

  Total revenue grew by 112.6% to $3.77 billion in Q1 2026, primarily driven by a 127.9% increase in digital asset sales revenue.

• Assets on Platform and Staked Assets Decline

  Assets on Platform decreased by 30.4% to $63.0 billion, and Assets Staked fell by 58.4% to $11.8 billion, largely due to digital asset price declines.

• Material Weaknesses in Internal Controls Persist

  The company continues to report un-remediated material weaknesses in its internal control over financial reporting, with remediation efforts expected to continue throughout 2026.

auto_awesomeAnalysis

This quarterly report reveals a mixed financial picture for BitGo. While the company achieved substantial revenue growth, its net losses significantly increased, and Adjusted EBITDA turned negative. Crucially, key operational metrics like Assets on Platform and Assets Staked saw considerable declines, indicating a challenging environment for digital asset values despite client growth. The continued presence of un-remediated material weaknesses in internal controls raises governance concerns, and the upcoming trial in the $100 million Galaxy Digital lawsuit adds a significant legal risk. Investors will focus on the company's ability to stem losses, stabilize platform asset values, and resolve its internal control deficiencies.